<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373840</url>
  </required_header>
  <id_info>
    <org_study_id>201102481</org_study_id>
    <nct_id>NCT01373840</nct_id>
  </id_info>
  <brief_title>Role of Dopamine Receptors in Primary Focal Dystonias</brief_title>
  <official_title>Role of Dopamine Receptors in Primary Focal Dystonias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dystonia is a disabling movement disorder characterized by repetitive patterned or sustained&#xD;
      muscle contractions causing twisting or abnormal postures that may afflict 250,000 people in&#xD;
      the U.S. While the pathophysiology of dystonia remains uncertain the treatment is rather&#xD;
      rudimentary. A better understanding of neural mechanisms of dystonias is not only an&#xD;
      invaluable prerequisite for developing better treatment options but also a step toward better&#xD;
      understanding of the complex network of basal ganglia. In this study I will investigate if&#xD;
      there is any difference between the dopamine receptors and dopamine in people with dystonia&#xD;
      and healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <condition>Focal Dystonias</condition>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with focal dystonias</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Any healthy control or patient with primary focal dystonia or arm or face.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;20&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Any race or ethnicity&#xD;
&#xD;
          -  Primary focal dystonia (arm or cranial)&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Family history of dystonia&#xD;
&#xD;
          -  Pregnancy (confirmed with negative urine pregnancy test in women of child bearing&#xD;
             potential), breastfeeding&#xD;
&#xD;
          -  Exposure to radiation therapy&#xD;
&#xD;
          -  Any MRI contraindications such as foreign metallic implants, pacemaker, and aneurysm&#xD;
             clip etc.&#xD;
&#xD;
          -  History of cardiac disease, uncontrolled hypertension, abnormal EKG during screening&#xD;
             phase&#xD;
&#xD;
          -  History of exposure to any drugs affecting dopaminergic systems within the last 6&#xD;
             months (e.g. dopamine receptor blocking agents, cocaine, amphetamine, tetrabenazine,&#xD;
             reserpine, L-dopa, dopamine agonists, as they might affect the dopamine receptor&#xD;
             binding or endogenous dopamine).&#xD;
&#xD;
          -  Active depression (Beck Depression Inventory_II &gt;14)&#xD;
&#xD;
          -  Cognitive impairment (Mini-Mental State Score &lt;27)&#xD;
&#xD;
          -  CNS active medications such as gabapentin or narcotics, muscle relaxants which might&#xD;
             be given for pain in the 3 days prior to study&#xD;
&#xD;
          -  History of stroke, seizure, cerebral palsy, generalized dystonia, parkinsonism,&#xD;
             inability to hold head still during the scanning time.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perlmutter Joel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>June 10, 2011</study_first_submitted>
  <study_first_submitted_qc>June 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2011</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>focal</keyword>
  <keyword>dystonia</keyword>
  <keyword>dopamine</keyword>
  <keyword>receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

